Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 12 5 versus ADHANSIA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 12 5 versus ADHANSIA XR.
ADDERALL 12.5 vs ADHANSIA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.
Adhansia XR is a central nervous system (CNS) stimulant. The mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully known, but it is thought to involve blockade of norepinephrine and dopamine reuptake into presynaptic neurons, increasing their levels in the synaptic cleft. This enhances attention and reduces impulsivity.
5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.
Methylphenidate hydrochloride extended-release: Oral, 18-72 mg once daily in the morning.
None Documented
None Documented
The terminal elimination half-life of d-amphetamine is approximately 10–13 hours in adults (range 9–14 h) and 6–8 hours in children. Clinical context: Typically allows twice-daily dosing; extended-release formulations provide 8–12 hours of effect.
Mean terminal elimination half-life is 7.5 hours (range 5-10 hours) following oral administration, allowing twice-daily dosing.
Approximately 30% of the dose is excreted unchanged in urine; the remainder is metabolized primarily via deamination and oxidation. Renal elimination of unchanged amphetamine is pH-dependent: acidic urine increases elimination, alkaline urine decreases it. Fecal excretion accounts for <5%.
Primarily renal (78% as unchanged drug), with 10% biliary/fecal elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant